Company news
Humacyte, Inc. news in 2025
Humacyte, Inc.'s news releases, calls and decks from 2025, newest first.
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
December 22, 2025
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
December 16, 2025
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
November 20, 2025
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
November 13, 2025
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
November 10, 2025
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
November 6, 2025
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
October 30, 2025
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
October 7, 2025
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™
October 6, 2025
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
September 29, 2025
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
September 18, 2025
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
September 15, 2025
Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update
August 11, 2025
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
August 7, 2025
Humacyte Announces First Symvess™ Sale to Military Treatment Facility
July 23, 2025
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
July 8, 2025
Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
June 9, 2025
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
June 2, 2025
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
May 19, 2025
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
May 9, 2025
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
March 28, 2025
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
March 26, 2025
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
March 25, 2025
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
March 25, 2025
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
March 10, 2025
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
March 3, 2025
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
February 27, 2025
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
February 27, 2025
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
February 26, 2025
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
January 27, 2025
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
January 20, 2025
Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
January 12, 2025
Calls in 2025
Decks in 2025
- Investor Presentation (March 2025)
Investor deck · 52 slides · Mar 25, 2025